COVID-19 recently emerged as a public health crisis due to the global spread of SARS-CoV2. Highly contagious through respiratory droplets and with a high mortality rate in vulnerable populations, there are currently no drug therapies with established safety and efficacy for clinicians to treat their patients.
There are reports of clinical treatments with off-label drug therapies that provide some evidence of patient improvement, thus there could be commercially available treatments that may be effective for treating COVID-19.
Because of this, it is critical to rapidly develop and implement a clinical protocol to generate evidence in a well-controlled clinical trial to establish the safety and efficacy of potential life-saving treatments.
GCAR is joining REMAP-CAP (A Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) and the University of Pittsburgh in a partnership to conduct REMAP-COVID; a platform trial for hospitalized COVID-19 patients in the US.
The REMAP-COVID platform has deployed new domain modules for anti-viral and immunomodulatory therapies targeted against COVID-19 and is actively enrolling COVID-19 patients in 13 countries. New domains will be added as knowledge of potentially effective therapies evolve.
The objective of REMAP-COVID is to reduce mortality and morbidity in patients hospitalized with COVID-19 infection by quickly generating new evidence on available and novel treatments. Through partnerships with academia, industry and multiple healthcare systems, GCAR is sponsoring REMAP-COVID in the US with the University of Pittsburgh serving as the US Regional Coordinating Center for REMAP-CAP.
For more information regarding the trial please visit:
Questions, please email Stephanie K. Montgomery at, email@example.com